Zobrazení zdroje stránky Alssinclair0449

o visceral metastasis and receive no prior tamoxifen or endocrine therapy, but the first-line fulvestrant therapy in this study.<br /><br />Fulvestrant has definite efficacy in treating ER-positive metastatic breast cancer and results in tolerable adverse reactions, while it notably extends the mPFS of patients who have no visceral metastasis and receive no prior tamoxifen or endocrine therapy, but the first-line fulvestrant therapy in this study.<br /><br /> To investigate the effects of micro ribonucleic acid (miR)-125b on the growth and apoptosis of malignant melanoma (MM) cells and related mechanisms.<br /><br /> The differences in the expressions of miR-125b and neural cell adhesion molecule-120 (NCAM-120), NCAM-140 and NCAM-180 in 5 cases of MM tissues (MM group) and corresponding adjacent tissues (Paracancer group) as well as MM cells were detected via quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry, respectively. Next, malignant melanoma A375 cells were selected to exogenously overexpress miR-125 (miR-125 mimic group). Then, in vitro functional assays were conducted to determine the influences of miR-125b on the proliferation, migration and apoptosis of MM cells, and the changes in the binding of miR-125b to the 3&amp;#39;-untranslated region (3&amp;#39;-UTR) of wild-type and mutant NCAM messenger RNAs (mRNAs) were verified using dual-luciferase assay.<br /><br /> MiR-125b was significantly lowly expressed in MM tissues and cells (p&amp;lt;0.01), while NCAM-120, NCAM-140 and NCAM-180 were clearly highly expressed in MM tissues and cells (p&amp;lt;0.05). After miR-125b was exogenously overexpressed in A375 cells, the proliferation and migration ability of A375 cells was decreased, whereas the proportion of apoptotic cells rose (p&amp;lt;0.05). [https://www.selleckchem.com/products/Axitinib.html read more] Besides, the results of dual-luciferase reporter assay revealed that the luciferase activity of A375 cells in the 3&amp;#39;-UTR of wild-type NCAM mRNA was overtly lowered compared with that of mutant NCAM mRNA (p&amp;lt;0.05).<br /><br /> MiR-125b acts as a tumor suppressor in MM cells by targeting and binding to NCAM.<br /><br />MiR-125b acts as a tumor suppressor in MM cells by targeting and binding to NCAM.<br /><br /> Uveal melanoma (UM) is one of the primary intraocular malignancies. Emerging studies have confirmed dysregulation of microRNA (miRNA/miR) in UM. The present study focused on the biofunctions of miR-137 in UM.<br /><br /> MiR-137 expressions in tissue samples were analyzed by qRT-PCR. MTT and transwell assays were applied to investigate the impacts of miR-137 on UM cell proliferation, invasion and migration. Luciferase assay was carried out to explore the downstream target of miR-137. Western blot was used to analyze the roles of miR-137 in UM cells, Wnt/β-catenin pathway and epithelial-mesenchymal transition (EMT).<br /><br /> qRT-PCR showed that miR-137 expressions were lower in UM tissue samples than para-carcinoma tissues, whereas EZH2 was simultaneously upregulated. MiR-137 overexpression evidently suppressed UM cell proliferation, invasion and migration. The findings also indicated that miR-137 restoration could block Wnt/β-catenin pathway and EMT in UM cells thus resulting in downregulation of malignant behaviors. EZH2 was a downstream target of miR-137 as demonstrated by luciferase assay.<br /><br /> The present study indicated that EZH2 participated in the anti-UM functions of miR-137. Taken together, the data in our study established miR-137/EZH2 axis in regulating UM progression, suggesting that miR-137 may function as a novel therapeutic biomarker for UM patients.<br /><br />The present study indicated that EZH2 participated in the anti-UM functions of miR-137. Taken together, the data in our study established miR-137/EZH2 axis in regulating UM progression, suggesting that miR-137 may function as a novel therapeutic biomarker for UM patients.<br /><br /> To explore the efficacy and related prognostic factors of acute myeloid leukemia (AML) in children except acute promyelocytic leukemia (APL).<br /><br /> The clinical data of 89 non-APL children with AML treated in our hospital were retrospectively analyzed. The remission status was analyzed after chemotherapy, the long-term survival was evaluated using the Kaplan-Meier method, and the influencing factors for the prognosis were detected using univariate and multivariate Cox regression analyses.<br /><br /> Complete remission (CR) was realized in 71 cases (79.8%) after the first course of treatment, 13 cases (14.6%) after the second course of treatment, and 5 cases (5.6%) after the third course of treatment. The 5-year event-free survival (EFS) rate and overall survival (OS) rate were 53.9% and 66.3%, respectively. The children were divided into low-risk group (n=31), middle-risk group (n=36) and high-risk group (n=22). In the three groups, the 5-year OS rate was 74.2%, 72.2% and 45.5%, respectively, while the 5-year EFS rate wiagnosis, CD56+ and recurrence time less then 1 year, and CR achieved after the first course is an independent factor improving the prognosis of patients. The long-term EFS rate is significantly lower in high-risk group than that in low- and middle-risk groups. Intensive chemotherapy or early hematopoietic stem cell transplantation should be performed for high-risk patients.<br /><br /> To explore the efficacy of chimeric antigen receptor (CAR)-T cell therapy in children with relapsed or refractory acute B-lymphocytic leukemia (B-ALL) and the influencing factors for their prognosis.<br /><br /> A retrospective analysis was performed on the clinical data of 46 children with relapsed or refractory B-ALL, who were admitted to and treated in our hospital from January 2015 to October 2017, and the remission and post-infusion adverse reactions were observed in all the patients. Besides, the survival of the patients was followed up and recorded, and the influencing factors for the prognosis were identified by univariate and multivariate Cox regression analyses.<br /><br /> Bone marrows were routinely monitored after infusion of CAR-T cells. It was found that 35 children patients achieved morphologic complete remission, had a lower level of minimal residual disease (MRD) than that before treatment and exhibited a response rate of 76.1%, of whom there were 33 cases of MRD-negative remission. Different degrees of cytokine release syndrome (CRS) occurred in 41 out of 46 children, consisting of 37 (80.